{"entity":{"type":"insider","cik":"0001726403","url":"/insider/0001726403","json_url":"/insider/0001726403.json","name":"Vivo Opportunity Fund, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":40,"n_filings":10,"first":"2018-07-20","last":"2022-01-31","span_basis":"filed_date"},"name_variants":[{"name":"Vivo Opportunity Fund, L.P.","source":"filing","n_filings":10,"first_seen":"2018-07-20","last_seen":"2022-01-31"}],"transactions":[{"id":6789207,"accession":"0001213900-22-004647","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001213900-22-004647","line_url":"/filing/0001213900-22-004647#line-1","is_derivative":false,"issuer_cik":"0001290149","issuer_name":"Sierra Oncology, Inc.","issuer_ticker":"SRRA","issuer_name_source":null,"issuer_url":"/issuer/0001290149","owner_cik":null,"owner_name":"Vivo Ventures Fund VII, L.P.; Vivo Opportunity, LLC; Vivo Opportunity Fund, L.P.; VIVO VENTURES VII, LLC; Vivo Ventures VII Affiliates Fund, L.P.; Vivo Capital Fund IX, L.P.; Vivo Capital IX, LLC","owner_display_name":"Vivo Ventures Fund VII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":800000.0,"shares_display":"800,000","price_per_share":27.0,"price_display":"27.00","price_state":"stated","total_value":21600000.0,"total_display":"21,600,000.00","total_whole":"21,600,000","shares_owned_after":2735853.0,"shares_owned_after_display":"2,735,853","ownership_form":"I","is_10b5_1":null,"transaction_date":"2022-01-31","filed_date":"2022-01-31","scope":"insider"},{"id":5107551,"accession":"0001567619-21-002591","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001567619-21-002591","line_url":"/filing/0001567619-21-002591","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Terns Pharmaceuticals, Inc.","issuer_ticker":"TERN","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Capital Surplus Fund VIII, L.P.; Vivo Opportunity Fund, L.P.; Vivo Opportunity, LLC; Vivo Capital Fund VIII, L.P.; Vivo Capital VIII, LLC","owner_display_name":"Vivo Capital Surplus Fund VIII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":475000.0,"shares_display":"475,000","price_per_share":17.0,"price_display":"17.00","price_state":"stated","total_value":8075000.0,"total_display":"8,075,000.00","total_whole":"8,075,000","shares_owned_after":357353.0,"shares_owned_after_display":"357,353","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-02-09","filed_date":"2021-02-09","scope":"insider","n_lines":3},{"id":4924723,"accession":"0001209191-21-008758","txn_seq":14,"anchor":"line-14","filing_url":"/filing/0001209191-21-008758","line_url":"/filing/0001209191-21-008758","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Bolt Biotherapeutics, Inc.","issuer_ticker":"BOLT","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Panda, LLC; Vivo Opportunity Fund, L.P.; Vivo Panda Fund, L.P.; Vivo Capital Surplus Fund VIII, L.P.; Vivo Opportunity, LLC; Vivo Capital VIII, LLC; Vivo Capital Fund VIII, L.P.","owner_display_name":"Vivo Panda, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":226.0,"shares_display":"226","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":4520.0,"total_display":"4,520.00","total_whole":"4,520","shares_owned_after":1821483.0,"shares_owned_after_display":"1,821,483","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-02-09","filed_date":"2021-02-09","scope":"insider","n_lines":3},{"id":4924713,"accession":"0001209191-21-008758","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0001209191-21-008758","line_url":"/filing/0001209191-21-008758","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Bolt Biotherapeutics, Inc.","issuer_ticker":"BOLT","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Panda, LLC; Vivo Opportunity Fund, L.P.; Vivo Panda Fund, L.P.; Vivo Capital Surplus Fund VIII, L.P.; Vivo Opportunity, LLC; Vivo Capital VIII, LLC; Vivo Capital Fund VIII, L.P.","owner_display_name":"Vivo Panda, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":7,"other_reporting_owners":6,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":350000.0,"shares_display":"350,000","price_per_share":20.0,"price_display":"20.00","price_state":"stated","total_value":7000000.0,"total_display":"7,000,000.00","total_whole":"7,000,000","shares_owned_after":1997216.0,"shares_owned_after_display":"1,997,216","ownership_form":"I","is_10b5_1":null,"transaction_date":"2021-02-09","filed_date":"2021-02-09","scope":"insider","n_lines":3},{"id":2857763,"accession":"0000899243-20-019915","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000899243-20-019915","line_url":"/filing/0000899243-20-019915","is_derivative":false,"issuer_cik":"0001726403","issuer_name":"ALX ONCOLOGY HOLDINGS INC","issuer_ticker":"ALXO","issuer_name_source":null,"issuer_url":"/issuer/0001726403","owner_cik":null,"owner_name":"Vivo Opportunity, LLC; Vivo Capital Fund IX, L.P.; Vivo Opportunity Fund, L.P.; Vivo Capital IX, LLC","owner_display_name":"Vivo Opportunity, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":975000.0,"shares_display":"975,000","price_per_share":19.0,"price_display":"19.00","price_state":"stated","total_value":18525000.0,"total_display":"18,525,000.00","total_whole":"18,525,000","shares_owned_after":789474.0,"shares_owned_after_display":"789,474","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-07-21","filed_date":"2020-07-21","scope":"insider","n_lines":2},{"id":2977306,"accession":"0001213900-20-006030","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001213900-20-006030","line_url":"/filing/0001213900-20-006030","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Crinetics Pharmaceuticals, Inc.","issuer_ticker":"CRNX","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Capital Surplus Fund VIII, L.P.; Vivo Capital Fund VIII, L.P.; Vivo Opportunity Fund, L.P.; Vivo Opportunity, LLC; Vivo Capital VIII, LLC","owner_display_name":"Vivo Capital Surplus Fund VIII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":528.0,"shares_display":"528","price_per_share":19.5,"price_display":"19.50","price_state":"stated","total_value":10296.0,"total_display":"10,296.00","total_whole":"10,296","shares_owned_after":2722045.0,"shares_owned_after_display":"2,722,045","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-03-09","filed_date":"2020-03-11","scope":"insider","n_lines":3},{"id":2799588,"accession":"0001213900-20-003326","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001213900-20-003326","line_url":"/filing/0001213900-20-003326","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Crinetics Pharmaceuticals, Inc.","issuer_ticker":"CRNX","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Capital Surplus Fund VIII, L.P.; Vivo Capital Fund VIII, L.P.; Vivo Opportunity Fund, L.P.; Vivo Capital VIII, LLC; Vivo Opportunity, LLC","owner_display_name":"Vivo Capital Surplus Fund VIII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7555.0,"shares_display":"7,555","price_per_share":21.4,"price_display":"21.40","price_state":"stated","total_value":161677.0,"total_display":"161,677.00","total_whole":"161,677","shares_owned_after":168298.0,"shares_owned_after_display":"168,298","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-02-10","filed_date":"2020-02-11","scope":"insider","n_lines":3},{"id":2799575,"accession":"0001213900-20-003326","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001213900-20-003326","line_url":"/filing/0001213900-20-003326","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Crinetics Pharmaceuticals, Inc.","issuer_ticker":"CRNX","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Capital Surplus Fund VIII, L.P.; Vivo Capital Fund VIII, L.P.; Vivo Opportunity Fund, L.P.; Vivo Capital VIII, LLC; Vivo Opportunity, LLC","owner_display_name":"Vivo Capital Surplus Fund VIII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5905.0,"shares_display":"5,905","price_per_share":22.0,"price_display":"22.00","price_state":"stated","total_value":129910.0,"total_display":"129,910.00","total_whole":"129,910","shares_owned_after":174202.0,"shares_owned_after_display":"174,202","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-02-07","filed_date":"2020-02-11","scope":"insider","n_lines":3},{"id":2517944,"accession":"0001213900-20-002831","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001213900-20-002831","line_url":"/filing/0001213900-20-002831","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Crinetics Pharmaceuticals, Inc.","issuer_ticker":"CRNX","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Capital VIII, LLC; Vivo Opportunity, LLC; Vivo Capital Surplus Fund VIII, L.P.; Vivo Capital Fund VIII, L.P.; Vivo Opportunity Fund, L.P.","owner_display_name":"Vivo Capital VIII, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13460.0,"shares_display":"13,460","price_per_share":22.8,"price_display":"22.80","price_state":"stated","total_value":306888.0,"total_display":"306,888.00","total_whole":"306,888","shares_owned_after":178816.0,"shares_owned_after_display":"178,816","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-02-04","filed_date":"2020-02-06","scope":"insider","n_lines":3},{"id":3096594,"accession":"0001213900-20-002314","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001213900-20-002314","line_url":"/filing/0001213900-20-002314","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Crinetics Pharmaceuticals, Inc.","issuer_ticker":"CRNX","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Capital VIII, LLC; Vivo Opportunity, LLC; Vivo Capital Surplus Fund VIII, L.P.; Vivo Capital Fund VIII, L.P.; Vivo Opportunity Fund, L.P.","owner_display_name":"Vivo Capital VIII, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5400.0,"shares_display":"5,400","price_per_share":21.7,"price_display":"21.70","price_state":"stated","total_value":117180.0,"total_display":"117,180.00","total_whole":"117,180","shares_owned_after":189335.0,"shares_owned_after_display":"189,335","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-01-31","filed_date":"2020-01-31","scope":"insider","n_lines":3},{"id":3096581,"accession":"0001213900-20-002314","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001213900-20-002314","line_url":"/filing/0001213900-20-002314","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Crinetics Pharmaceuticals, Inc.","issuer_ticker":"CRNX","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Capital VIII, LLC; Vivo Opportunity, LLC; Vivo Capital Surplus Fund VIII, L.P.; Vivo Capital Fund VIII, L.P.; Vivo Opportunity Fund, L.P.","owner_display_name":"Vivo Capital VIII, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7600.0,"shares_display":"7,600","price_per_share":22.1,"price_display":"22.10","price_state":"stated","total_value":167960.0,"total_display":"167,960.00","total_whole":"167,960","shares_owned_after":193555.0,"shares_owned_after_display":"193,555","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-01-30","filed_date":"2020-01-31","scope":"insider","n_lines":3},{"id":3096569,"accession":"0001213900-20-002314","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001213900-20-002314","line_url":"/filing/0001213900-20-002314","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Crinetics Pharmaceuticals, Inc.","issuer_ticker":"CRNX","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Capital VIII, LLC; Vivo Opportunity, LLC; Vivo Capital Surplus Fund VIII, L.P.; Vivo Capital Fund VIII, L.P.; Vivo Opportunity Fund, L.P.","owner_display_name":"Vivo Capital VIII, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13920.0,"shares_display":"13,920","price_per_share":22.2,"price_display":"22.20","price_state":"stated","total_value":309024.0,"total_display":"309,024.00","total_whole":"309,024","shares_owned_after":199495.0,"shares_owned_after_display":"199,495","ownership_form":"I","is_10b5_1":null,"transaction_date":"2020-01-29","filed_date":"2020-01-31","scope":"insider","n_lines":3},{"id":7988843,"accession":"0001615774-19-004434","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001615774-19-004434","line_url":"/filing/0001615774-19-004434","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Crinetics Pharmaceuticals, Inc.","issuer_ticker":"CRNX","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Capital Surplus Fund VIII, L.P.; Vivo Capital Fund VIII, L.P.; Vivo Opportunity Fund, L.P.; Vivo Capital VIII, LLC; Vivo Opportunity, LLC","owner_display_name":"Vivo Capital Surplus Fund VIII, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":5,"other_reporting_owners":4,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":417000.0,"shares_display":"417,000","price_per_share":22.25,"price_display":"22.25","price_state":"stated","total_value":9278250.0,"total_display":"9,278,250.00","total_whole":"9,278,250","shares_owned_after":2732730.0,"shares_owned_after_display":"2,732,730","ownership_form":"I","is_10b5_1":null,"transaction_date":"2019-03-20","filed_date":"2019-03-25","scope":"insider","n_lines":3},{"id":6756874,"accession":"0001615774-18-006729","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001615774-18-006729","line_url":"/filing/0001615774-18-006729","is_derivative":false,"issuer_cik":"0001618788","issuer_name":"Crinetics Pharmaceuticals, Inc.","issuer_ticker":"CRNX","issuer_name_source":null,"issuer_url":"/issuer/0001618788","owner_cik":null,"owner_name":"Vivo Capital, LLC; Vivo Capital Surplus Fund VIII, L.P.; Vivo Capital Fund VIII, L.P.; Vivo Opportunity Fund, L.P.; Vivo Capital VIII, LLC; Vivo Opportunity, LLC","owner_display_name":"Vivo Capital, LLC","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"P","transaction_label":"Open-market purchase","open_market":true,"acquired_disposed":"A","direction_word":"acquired","shares":353180.0,"shares_display":"353,180","price_per_share":18.61776261396455,"price_display":"18.62","price_state":"stated","total_value":6575421.4,"total_display":"6,575,421.40","total_whole":"6,575,421","shares_owned_after":294357.0,"shares_owned_after_display":"294,357","ownership_form":"I","is_10b5_1":null,"transaction_date":"2018-07-20","filed_date":"2018-07-20","scope":"insider","n_lines":4}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":0,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":0,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":0},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001290149","name":"Sierra Oncology, Inc.","url":"/issuer/0001290149","role":"Ten percent owner","n_filings":1,"first_seen":"2022-01-31","last_seen":"2022-01-31"},{"type":"issuer","type_label":"ISSUER","cik":"0001641281","name":"Bolt Biotherapeutics, Inc.","url":"/issuer/0001641281","role":"Ten percent owner","n_filings":1,"first_seen":"2021-02-09","last_seen":"2021-02-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001831363","name":"Terns Pharmaceuticals, Inc.","url":"/issuer/0001831363","role":"Ten percent owner","n_filings":1,"first_seen":"2021-02-09","last_seen":"2021-02-09"},{"type":"issuer","type_label":"ISSUER","cik":"0001810182","name":"ALX ONCOLOGY HOLDINGS INC","url":"/issuer/0001810182","role":"Ten percent owner","n_filings":1,"first_seen":"2020-07-21","last_seen":"2020-07-21"},{"type":"issuer","type_label":"ISSUER","cik":"0001658247","name":"Crinetics Pharmaceuticals, Inc.","url":"/issuer/0001658247","role":"Ten percent owner","n_filings":6,"first_seen":"2018-07-20","last_seen":"2020-03-11"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001726403","retrieved_at":"2026-08-23T19:50:53+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}